Human herpesvirus 
INTRODUCTION
Human herpesviruses type 6 (HHV-6) and type 7 (HHV-7) belong to the Roseolovirus genus within the beta-herpesvirus subfamily. Both of the viruses are highly prevalent in the healthy population, establishing latency in the human host after the primary infection, and can become reactivated in immunosuppressive individuals (Chapenko et al., 2001; Kozireva et al., 2001 ).
HHV-6, initially termed human B-lymphotropic virus, was first isolated in 1986 from patients with various lymphoproliferative disorders (Salahuddin et al., 1986) . There are two distinct variants of HHV-6 -HHV6A and HHV-6B (Ablashi et al., 1993) . With the exception of a few genes or regions, the coding sequences of HHV-6A and HHV-6B are identical for more than 90% (Isegawa et al., 1999) . HHV-6 (A and B variants) reactivation occurs in approximately 50% of bone marrow and solid organ transplant recipients. The consequences of HHV-6 reactivation include cytomegalovirus (CMV) reactivation, bone marrow suppression, central nervous system dysfunction, idiopathic pneumonitis, severe graft-versus-host disease, hepatitis fulminant liver failure and increased mortality (Chapenko et al., 2001; Caselly et al., 2007) .
HHV-7, first isolated from CD4+ T cells of healthy individuals in 1990, has been implicated as a cause of neurological manifestations and can act as a cofactor for HHV-6 activation and CMV disease development in transplant patients (Frenkel et al., 1990; Chan et al., 2004; Caselly et al., 2007) .
The lack of a standardised assay for detection of HHV-6 and HHV-7 DNA can lead to discordant results among investigators on potential association of these viruses with the diseases. The sensitivity of the assay is a very important issue, considering that HHV-6 and HHV-7 generally remain cell-associated and that the detection of cell-free HHV-6 and HHV-7 in biological samples can be clinically meaningful. Moreover, the routine diagnostic of HHV-6 and HHV-7 infections in Latvia is lacking. The aim of this study was to identify the most reliable and sensitive nested polymerase chain reaction (nPCR) assays for detection of HHV-6 and HHV-7. We compared the sensitivity of six nPCR assays for HHV-6 and four nPCR assays for HHV-7 and determined the reproducibility of the selected nPCR assays in five different laboratories. In all cases, the amplification reactions were performed in a volume of 50 µl as previously described (Hall et al., 1994; Challoner et al., 1995; Secchiero et al., 1995; Ueda et al., 1996; Chan et al., 1999; Gonelli et al., 2001) and the amplification products were analysed by agarose gel electrophoresis followed by ethidium bromide staining.
MATERIALS AND METHODS

Evaluation
To determine the minimal detection limit of these HHV-6 and HHV-7 nPCR assays, serial dilutions of HHV-6 and HHV-7 commercial DNA controls were used as a template for PCR amplification. To determine reproducibility of HHV-6 and HHV-7 nPCRs each nPCR assay was tested by using dilution series of HHV-6 and HHV-7 DNAs in 10 repeats for each dilution.
Interlaboratory evaluation of reproducibility of the two selected HHV-6 and HHV-7 nPCR assays. Blood samples from 20 renal transplant patients, as well as from 20 patients with colorectal cancer, were tested at least two times in our laboratory for the presence of HHV-6 and HHV-7 genomic sequences using two of the most sensitive nPCR assays. The investigation was carried out with approval of Ethics Committee of Rîga Stradiòð University and all patients gave their informed consent prior to the examination.
DNA from the HOS cell line was used as a negative amplification control. DNA was purified from peripheral blood leukocytes by proteinase K digestion and extraction by standard phenol-chloroform technique as described before (Murovska et al., 2000) .
Each of the five testing laboratories (Latvian State Blood Centre, Latvian State Agency for Tuberculosis and Lung Diseases, National Diagnostic Centre of Food and Veterinary Service, Latvian Biomedical Research and Study Centre, Genera Ltd.) had received six coded samples: four clinical DNA samples, one positive amplification control (containing 20 copies of the entire virus/µl) and one negative amplification control (DNA from HOS cell line). All samples were arranged in a blinded fashion. Each laboratory was using the same amplification protocols (including their own non-template or PCR reagent control) to confirm the reproducibility of these assays.
Sequencing analysis. The amplimers, obtained from three HHV-6 positive patients and three HHV-7 positive patients by using the selected Bgp071 HHV-6 and NPP HHV-7 nPCR assays were cloned into a cloning vector pTZ57R/T by using the InsTAclone™ PCR Cloning Kit (Fermentas, Lithuania) and sequenced on an ABI 310 capillary electrophoresis system (Applied Biosystems, Foster City, CA) using the BigDye terminator v3.1 sequencing kit. The sequences were further analysed with the BLAST alignment programme.
RESULTS
Evaluation of the sensitivity and intralaboratory reproducibility of different HHV-6 and HHV-7 nPCR assays.
We compared the performance of six different nPCR assays targeting four different HHV-6 genes and four nPCRs assays targeting four different HHV-7 genes by testing the serial dilutions of HHV-6 and HHV-7 commercial DNA controls (Table I) .
The HHV-6 nPCRs targeting Bgp009, LTP and Bgp071 genes had the same sensitivity and allowed to detect 10 genome copies of both A and B variants of HHV-6. The sensitivity of HHV-6 nPCR targeting MBP gene was 50 copies for both HHV-6 variants, nPCR with the second set of primers targeting LTP gene -25 copies of HHV-6A and 50 of HHV-6B, respectively, while the nPCR assay with the second set of primers targeting Bgp071 gene was the most sensitive and could detect five genome copies of both A and B variants of HHV-6 ( Fig. 1 and Table 2 ). The sensitivity of HHV-7 LTP and TPP nPCR assays was five copies and one copy for nPCRs targeting IE-A transactivator and NPP genes ( Fig. 2 and Large tegument protein gene 447 bp Gonelli et al., 2001 Immediately early A transactivator gene 140 bp Gonelli et al., 2001 The reproducibility of each nPCR assay was examined by testing dilution series of HHV-6 and HHV-7 DNAs in 10 repeats for each dilution. The results showed that all six HHV-6 nPCRs had the same reproducibility (10 of 10 repeats). The identical reproducibility was observed also using HHV-7 specific nPCRs targeting TPP, LTP and NPP genes (10 out of 10 replicates), while the reproducibility of nPCR targeting EI-A gene of HHV-7 was detected in 8 of 10 repeats.
Interlaboratory reproducibility of the selected HHV-6 and HHV-7 nPCR assays. Five different laboratories using two of the most sensitive and reproducible HHV-6 and HHV-7 nPCR assays were asked to participate in this study. Each laboratory received different sets of six coded samples and performed the HHV-6 and HHV-7 analyses by the protocols provided by our (reference) laboratory. Upon completion, each laboratory was asked to send its results to the project coordinator. In all five laboratories any false-positive results for the HHV-6 and HHV-7 negative samples and controls as well as any negative results for HHV-6 and HHV-7 positive samples and controls were reported for these two assays. The obtained results confirmed the high reproducibility of these two nPCRs for detection of HHV-6 and HHV-7.
Sequencing analysis. Three amplimers from three HHV-6 positive renal transplant patients obtained by using the selected HHV-6 nPCR assay that could detect five genomic copies and targeted Bgp071 gene were cloned and analysed by sequencing. The obtained sequences were compared to all published genomic sequences of HHV-6: HHV-6A strain U1102 (X83413.1), HHV-6B strain Z29 (AF_157706.1) and HHV6B strain HST (AB_021506.1). Ten nucleotide substitutions were observed compared to the prototype genomic sequence of HHV-6A strain U1102, and two nucleotide substitutions -compared to the prototype genomic sequence of HHV-6B strain Z29, but the nucleotide sequences of all three patients were identical to genomic sequence of HHV-6B strain HST (Fig. 3) .
Three amplimers from three HHV-7 positive patients with colorectal cancer obtained by selected HHV-7 nPCR which could detect 1 genomic copy of HHV-7 and targeted NPP gene, were also cloned and analysed by sequencing. No nucleotide substitutions were found in these patients and the nucleotide sequences of all three patients were identical to prototype HHV-7 strain RK (NC_001716).
DISCUSSION
HHV-6 and HHV-7 are known as etiological agents of exanthema subitum (Caselly et al., 2007) . Both HHV-6 and Lane M, pUC19 DNA/MspI (HpaII) (Fermentas, Lithuania); lanes 100, 50, 25, 10, 5 and 1 -copy number of HHV-6 DNA per reaction. HHV-7 infect cells of the immune system and can modulate their functions (Lusso, 2006) . Both HHV-6 and HHV-7 are highly prevalent in the healthy population, after primary infection the viruses establish lifelong latency and the pathogenic potential of reactivated virus ranges from asymptomatic infection to severe diseases in immunosuppressed patients, especially in transplant recipients (Caselly et al., 2007) . PCR-based assays have been recognised as a sensitive and specific method for molecular detection and identification of HHV-6 and HHV-7. Different nPCR assays for detection of HHV-6 and HHV-7 have been reported, but none of these assays has been compared systematically.
There also are described various assays for quantitative HHV-6 and HHV-7 detection, based on TaqMan PCR technology, but those assays are very expensive, limiting their general use. Chronic HHV-6 and HHV-7 infections are difficult to detect since there is very little free virus circulating in serum. Therefore, there is urgent need for very sensitive diagnostic assays and for studies that can prove or disprove the importance of these viral infections in various pathological processes.
In this study we evaluated the sensitivity of the six previously described nPCRs assays for detection of HHV-6 and 4 nPCRs for detection of HHV-7. All six nPCR assays for HHV-6 can detect both HHV-6 variants. The most sensitive nPCR for HHV-6 detection was nPCR with primers targeting the Bgp071 gene. The minimal amount that could be reproducibly detected by this nPCR assay was five genomic copies of HHV-6 (A and B). The most sensitive and reproducible nPCR assay for detection of HHV-7 was nPCRs with primers targeting NPP gene. These assays could detect one copy of HHV-7.
HHV-6 specific amplimers (Bgp071 gene) of three renal transplant patients as well as HHV-7 specific amplimers (NPP gene) of three patients with colorectal cancer were cloned and analysed by sequencing. The results of sequencing of HHV-6 and HHV-7 positive amplimers confirmed the presence of HHV-6 or HHV-7 genomic sequences in these samples and demonstrated that all three patients had HHV-6B strain HST, since their nucleotide sequences were identical to this strain of HHV-6. All three HHV-7 positive patients had a nucleotide sequence identical to prototype HHV-7.
Taking into account that nPCR assays are associated with a high risk of contamination, the reproducibility of the most sensitive nPCRs, targeting to Bgp071 gene of HHV-6 and NPP gene of HHV-7, was evaluated in five different laboratories using the same nPCR protocol and DNA samples proved positive or negative in our laboratory. The identical results obtained in all five laboratories confirmed the reproducibility of these nPCR assays for HHV-6 and HHV-7 detection. No evidence of contamination was observed using these nPCR assays in all five laboratories indicating that these nPCR are useful as assays for detection of HHV-6 and HHV-7.
The pathogenesis of HHV-6 and HHV-7 infections, the methods for their diagnosis, as well as the evaluation of antiviral drugs and strategies for their prevention and treatment are now the subject of extensive research. Our study showed that the HHV-6 nPCR with primers targeted to Bgp071 gene and HHV-7 nPCR with primers targeted to NPP gene are sensitive and reproducible assays and may be useful for molecular diagnostics of HHV-6 and HHV-7 infection. Moreover, this study emphasises the importance of performing multi-institution experiments to provide a coherent basis for comparing results and to motivate standardisation of the methods.
